|Title:||Olanzapine polymorph crystal form|
|Abstract:||The invention provides Form II, a pharmaceutically elegant, stable polymorph of olanzapine useful for treating a condition selected from the group consisting of a psychotic condition, mild anxiety and gastrointestinal conditions.|
|Inventor(s):||Bunnell; Charles Arthur (Lafayette, IN), Hendriksen; Barry Arnold (Guildford, GB), Larsen; Samuel Dean (West Lafayette, IN)|
|Assignee:||Eli Lilly and Company (Indianapolis, IN) Eli Lilly and Company (Basingstoke, GB2)|
Patent Claim Types:|
see list of patent claims
|Composition; Formulation; Dosage form; Process; Use;|
Field: Basic materials chemistry
Back Citations: 6th percentile
Forward Citations: 2nd percentile
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|African Regional IP Organization (ARIPO)||828||► subscribe|
|African Regional IP Organization (ARIPO)||9701065||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.